| Document |
Document Title |
|
WO/2017/215680A2 |
Disclosed are a chlorprothixene pharmaceutical composition and effects thereof for protecting cerebral ischemia reperfusion injuries. The chlorprothixene pharmaceutical composition provided in the present invention comprises chlorprothix...
|
|
WO/2017/215538A1 |
Provided are a Mannich base derivative of acetylchrysin having a structrue of general formula I and a use thereof, wherein R1 and R2 are each independently selected from an acetyl and organic secondary amine methylene, and only one of R1...
|
|
WO/2017/216426A1 |
The invention relates to process for converting berry and/or fruit materials to fractions comprising bioactive compounds, said process comprising the steps, where at least one berry material or fruit material selected from berries, fruit...
|
|
WO/2017/212059A1 |
The present invention relates to a new process of manufacturing of caged cyclofen-OH and derivatives thereof, of formula (I) or salts thereof, wherein n, R1, R1 ', R2, and R3 are as defined in the claims.
|
|
WO/2017/214529A1 |
This disclosure relates to techniques and methods to isolate and purify cannabinoids, such as CBDV, CBD, CBC, THCV, THC, CBN, CBG, CBDA, THCA, or CBGA. Evaporation and sonicating techniques are used to isolate and purify cannabinoids, su...
|
|
WO/2017/207539A1 |
The invention relates to tetrahydropyranyl lower alkyl esters and particularly tetrahydropyranyl acetates, a method for producing same using ketene, and the use of same as fragrant and aromatic substances.
|
|
WO/2017/202798A1 |
The present invention provides novel compounds having the general formula (I) wherein R1 to R6, X, Y, A1 and A2 are as described herein, compositions including the compounds and methods of using the compounds.
|
|
WO/2017/205350A1 |
Molecular probes for detecting and imaging pancreatic cancer are disclosed. The probes are modified benzoxanthene fluorophores, which are selectively taken up by pancreatic cancer cells, such as pancreatic ductal adenocarcinoma cells. Em...
|
|
WO/2017/201581A1 |
The present invention relates to new desferrioxamine B-based compounds that may be useful to treat neurodegenerative diseases, to their preparation, and to compositions including the compounds. The present invention also relates to the u...
|
|
WO/2017/201531A1 |
Provided are a photoactive fluorophore, a photoactive ligand, and a photoactive complex. The photoactive fluorophore includes a photoactivatable derivative of an azetidine-containing Janelia-Fluor dye. The photoactive ligand includes a p...
|
|
WO/2017/195835A1 |
One purpose of the invention is to provide a technique for modifying polyphenols to suppress the occurrence of precipitation and turbidity in water without separate addition of food additives or conducting enzyme treatment. Modified poly...
|
|
WO/2017/194173A1 |
The present invention relates to methods for purifying one or two cannabinoid compounds using simulated moving bed chromatography, wherein the cannabinoid compound(s) is/are obtained in the extract and/or the raffinate with the total amo...
|
|
WO/2017/187321A1 |
The present invention provides for compounds of formula (I), wherein R1, m, Z, G1, R2, and R3 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment ...
|
|
WO/2017/185179A1 |
A method of increasing the self-renewal and/or expansion of hematopoietic stem and/or progenitor cells (HSPCs) is described. Inhibiting the activity and/or expression of cytochrome P450 1B1 (CYP1B1) and/or increasing the expression or ac...
|
|
WO/2017/184623A1 |
In one aspect, compounds of Formulae (I) and (II), or pharmaceutically acceptable salts thereof, are featured: Formulae (I) and (II), wherein the variables shown in Formulae (I) and (II) can be as defined anywhere herein.
|
|
WO/2017/184498A1 |
Processes for preparing compositions comprising substituted 1,2-dihydroquinolines and having low or undetectable levels of substituted anilines, wherein the processes comprise removing the substituted anilines from feed streams comprisin...
|
|
WO/2017/177919A1 |
Provided in the present invention is a compound as shown in formula (I), formula (II) or formula (III). The compound is capable of inhibiting the binding of the PB2 protein of the influenza virus to an RNA cap, and has a function of oppo...
|
|
WO/2017/181118A1 |
The present invention provides methods for producing cannabinoid prodrugs. Also described are pharmaceutically acceptable compositions of the prodrugs and a system for the large-scale production of the prodrugs.
|
|
WO/2017/175064A1 |
A method for the bio-enzymatic synthesis of tetrahydrocannabivarin (THC-v), cannabivarin (CBV) and cannabinol (CBN) by contacting a compound according to Formula I with a cannabinoid synthase enzyme. The cannabinoids are produced in the ...
|
|
WO/2017/177004A1 |
Compunds of Formula (I) and pharmaceutically acceptable salts thereof, wherein G1, G2, G3, L1, L2, and L3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by the modulation o...
|
|
WO/2017/156520A1 |
Disclosed are derivatives of icariin. Disclosed are compounds having Formula I-V as defined herein. Methods of using these compounds for the treatment of cancer and inflammation are also disclosed.
|
|
WO/2017/152539A1 |
Provided are a 4-sulfur pentafluoride phenol compound and a preparation method therefor, and a preparation method for a sulfur pentafluoride substituted benzopyran compound. According to the present invention, sulfur pentafluoride salicy...
|
|
WO/2017/146400A1 |
The present invention relates to a compound for detecting phosgene and DCP (diethyl chlorophosphate) and a composition for detecting phosgene and DCP (diethyl chlorophosphate) comprising the said compound. More precisely, the compound fo...
|
|
WO/2017/146466A1 |
The present specification relates to a heterocyclic compound and an organic light emitting element comprising the same.
|
|
WO/2017/139962A1 |
A method for extracting herbacetin from rhodiola rosea comprises the steps of: 1) extracting a medicinal material by using an extraction solvent, and then concentrating to obtain an extract paste; 2) extracting the extract paste, and aci...
|
|
WO/2017/135286A1 |
Provided are an urolithins-containing aqueous solution comprising urolithins and collagen, a dried solid composition thereof, and a production method therefor, and an urolithins stabilizing method.
|
|
WO/2017/132775A1 |
This invention provides novel compositions and methods for the treatment of leiomyoma. In some other aspects, this invention provides novel compositions and methods comprising prodrugs of (-)-epigallocatechin-3-gallate (EGCG) and prodrug...
|
|
WO/2017/131047A1 |
The presentt invention addresses the problem of providing a photocuring method that obtains a crosslinked product (resin) quickly and efficiently, a compound used in the photocuring method, and a photocurable resin composition containing...
|
|
WO/2017/125900A1 |
The present invention relates to a novel process for the synthesis of the intermediate compounds constituted by chromanyl haloketones of formula III and 6-fluoro-2-(oxiran-2-yl) chromans of formula I. The intermediates thus obtained can ...
|
|
WO/2017/125638A1 |
The invention relates to a method for the fluorescence-based determination of tertiary amines by means of reactants that use halogenated-xanthene-based dyes. The invention also relates to a kit comprising the reactants necessary for carr...
|
|
WO/2017/124949A1 |
The present invention relates to flavanone derivatives and a preparation method and use thereof, and in particular relates to the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composi...
|
|
WO/2017/121855A1 |
The present invention relates to compounds of formula (I) These compounds are useful in the treatment of many diseases such as a skin disease, an allergy, an autoimmune disease, a cardiovascular disease, a lung disease, asthma, a bacteri...
|
|
WO/2017/122722A1 |
The present invention provides: a compound represented by formula (1) as a pharmaceutical agent which is useful as a neuroregeneration promoting agent [in the formula, R1-L- represents R1-OC(O)-, etc., R1 represents a hydrogen atom, an o...
|
|
WO/2017/120591A1 |
The present disclosure provide a combination of a chromene compound having the structure of Formula (I), or pharmaceutically acceptable salts, and a second compound that can be selected from a PD-1 inhibitor, PD-L1 inhibitor, CTLA-4 inhi...
|
|
WO/2017/113013A1 |
The present disclosure provides biophotonic topical compositions, kits and their uses. In some aspects, the biophotonic topical compositions of the present disclosure comprise a first chromophore, a salt selected from one or more bicarbo...
|
|
WO/2017/111387A1 |
The present invention relates to a pseudo-ceramide compound and a preparation method therefor. The pseudo-ceramide compound of the present invention can provide an antioxidative effect, and can exhibit improved physical properties, such ...
|
|
WO/2017/111076A1 |
The invention provides an α,β unsaturated amide compound having anticancer activity shown by formula (I) or a pharmaceutically acceptable salt or the like thereof: [in the formula, A represents an optionally substituted heterocyclic di...
|
|
WO/2017/100882A1 |
This invention patent relates, in a first aspect, to cell staining compositions comprising a mixture of dyes or salts and complexes thereof in an aqueous medium and optionally a cell lysis agent. Also disclosed are methods for preparing ...
|
|
WO/2017/106786A1 |
Provided herein are methods for making an alpha-tocotrienol enriched tocol mixture, such as from a plant or plant-derived material. Also provided herein are simulated moving bed purification methods for tocotrienol compounds such as alph...
|
|
WO/2017/103840A1 |
The embodiments herein provides method for synthesizing water soluble forskolin 10% w/w. 250 litres of distilled water, 5 kg of pre-treated forskolin (98% w/w) and 20 kg of synthetic water soluble polymer are added into the reactor to ob...
|
|
WO/2017/103931A1 |
Compounds capable of, or usable in, killing cancer cells, and/or modulating a biological activity of a chemokine, and/or inhibiting a kinase, and/or treating diseases and disorders associated with a biological activity of a chemokine and...
|
|
WO/2017/106649A1 |
This disclosure is related to methods for producing anhydroryanodol, ryanodol, or analogues thereof and novel compounds prepared thereby.
|
|
WO/2017/105041A1 |
The present invention relates to a novel compound and an organic electroluminescent device comprising the same. The compound according to the present invention is used for an organic material layer of an organic electroluminescent device...
|
|
WO/2017/106074A1 |
Provided are methods of treating neonatal and young non-human animals, particularly pre-weaned animals, suffering from diarrhea, and/or symptoms thereof, by administering to an animal in need thereof a proanthocyanidin polymer compositio...
|
|
WO/2017/100869A1 |
This invention patent relates, in a first aspect, to cell staining compositions comprising a mixture of dyes or salts and complexes thereof in an aqueous medium and, optionally a cell lysis agent. Also disclosed are methods for preparing...
|
|
WO/2017/103295A1 |
The invention relates to coumarins of formula (I), polyols and polyurethanes produced from said coumarin, as well as the method for producing said polyurethanes, the use thereof in the preparation of coating films and method thereof for ...
|
|
WO/2017/097752A1 |
The invention relates to a configurational stereoisomer, referred to as enantiomer E2, of flocoumafen, said enantiomer E2 having, as determined by the chromatographic analysis of a flocoumafen composition comprising four configurational ...
|
|
WO/2017/097750A1 |
The invention relates to a configurational stereoisomer, referred to as enantiomer E4, of flocoumafen, said enantiomer E4 having, as determined by the chromatographic analysis of flocoumafen comprising four configurational stereoisomers ...
|
|
WO/2017/097755A1 |
The invention relates to a configurational stereoisomer, referred to as enantiomer E4, of bromadiolone, having, as determined by the chromatographic analysis carried out under conditions described hereinafter, a retention time t4 with a ...
|
|
WO/2017/097751A1 |
The invention relates to a configurational stereoisomer, referred to as enantiomer E3, of flocoumafen, said enantiomer E3 having, as determined by the chromatographic analysis of the flocoumafen, carried out under specific conditions, a ...
|
